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Recent studies have shown that the progression of
neoplastic lesions is characterised by the reactivation of
telomerase, a ribonucleoprotein complex which stabilizes
telomere length by adding hexameric repeat (TTAGGG)n
to telomeric ends of human chromosomes (1). Telomeres
are important for maintaining chromosome structure by
protecting the chromosomes from DNA degradation, end
to end fusions, rearrangement and chromosome loss
(2,3). Telomerase activity has been detected in germline
cells and most cancer cells, whereas most normal somatic
cells have no clearly detectable telomerase activity (4,5).
Because of this difference, telomerase activity is
considered to be a diagnostic marker of malignancy (6-8).

Current Methodologies
A number of methods for determining telomerase
activity have been developed. The detection of telomerase
activity using the conventional assay, which requires a
large amount of cell or tissues, has largely been replaced
by the telomeric repeat amplification protocol (TRAP)
described by Kim et al. (4). Because of several
disadvantages, numerous improvements have been made
to the original TRAP protocol, making the assay more
sensitive and reliable for potential clinical application.
I. The TRAP assay includes preparation of a protein
exctract by cell lysis and adding a primer and dNTPs. If
telomerase is active in the extract, it elongates the added
primer, and the reaction product (templates) is amplified
by PCR. This technique is highly sensitive but can provide
only qualitative (presence/absence) evaluation. For
quantitative analysis, the area or intensity of 6bp ladders
appearing in an X-ray film must be measured by
densitometry with a computer program, but the result

still depends on conditions of quantitative
autoradiography that do not easily produce precise
linearity and reproducibility (9). Commercial kits (Trapeze, TRAP-eze-xl, TRAP-eze-Elisa telomerase detection
kits from Oncor (Gaithersburg, MD, USA)) give increased
sensitivity with decreased sample processing time,
allowing improved detection of telomerase activity in a
large number of samples (10).
a. Aldous and Grabill (11) have introduced a
fluorescent method of detecting telomerase to alleviate
the problems including incorporation of radionucleotides
detected by autoradiography and the time required to
complete the assay. Telomeric repeats are identified in
the fluorescent TRAP (F-TRAP) assay by incorporation of
fluorescein labeled primers during amplification and
subsequent detection with an automated DNA sequencer.
b. Stretch PCR, a modification of TRAP, has beeen
developed for quantitation of telomerase activity (12).
The introduction of steps for purification of telomerase
products before PCR reaction and the use of specially
designed primers that contain unrelated internal
sequences of the templates contributes significantly to the
quantitative accuracy of the assay. Because the primers
used in the TRAP assay tend to anneal to internal
sequences of the templates and shorter products are
preferentially amplified, the primer (TAG-U and CTA-R)
used in stretch PCR eliminates this shortcoming and also
eliminates the possibility of obtaining false negative
results caused by the presence of PCR inhibitors in the
sample.
c. Gelmini et al. (13) presented a modification of the
TRAP method that can provide quantitative information
without requiring time-consuming post-PCR procedures
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such as gel electrophoresis with radioactive materials and
autoradiography. The detection and measurement of
telomerase activity is performed by evaluating the
amount of double-strand DNA generated in the
telomerase reaction and PCR amplification; with the use
of the fluorescent dye PicoGreen, which selectively binds
double strand DNA. The primers used in stretch PCR are
also maintained in this modification, and fluorescence is
measured in a spectrofluorophotometer.
d. Specific localization of telomerase activity in tumor
cells has been demonstrated using in situ PCR
modification of the TRAP assay that can be provide to
detect the telomerase activity at the cellular level (14).
II. Hirose et al. (15) described a new quantitative and
non-radioactive method, transcription mediated
amplification (TMA), in conjunction with the hybridization
protection assay (HPA), for telomerase activity. TMA is
not based on PCR; it uses an isothermal amplification
system that can be performed in a heat block or water
bath. In the TMA protocol, amplified telomerase products
are RNA and these amplifications are detected using a
non-isotopic HPA system. HPA uses an acridinium esterlabeled probe that hybridizes to the junction of the primer
and telomeric repeat. Quantitative analysis is based the
principle of differential hydrolysis of the bound and free
probe. The results are obtained easily by
chemiluminescence measurement in a luminometer. The
TMA/HPA method is faster than TRAP and as sensitive
and reproducible as the TRAP assay. In addition, Hirose
et al. showed that TMA/HPA is influenced minimally by
TRAP inhibitors that may come from clinical samples.
III. Recent studies have focused on analyzing the
expression level of telomerase components after the
cloning (16) of genes encoding the components of the

human telomerase complex including the telomerase RNA
component (hTERC) that acts as a template to add
telomeres to the ends of the chromosomes, telomerase
reverse transcriptase (hTERT) and telomerase protein
component 1 (hTEP1) (17). These improvements have
enabled the analysis of mRNA expression as an alternative
assessment of telomerase function by using a quantitative
reverse transcription (RT)-PCR assay. hTERT-mRNA
expression is closely associated with telomerase activity.
Analysis of the hTERT transcript may provide an
alternative method for determining the telomerase
activity (18-21). Expression levels of telomerase
components have also been demonstrated using nonradioactive in situ hybridization (22).
a. The Taq Man fluorogenic detection system has been
applied to the quantitative RT-PCR assay (real time PCR)
by Yajima et al. (23). This method utilizes the 5'
exonuclease activity of taq polimerase to cleave a nonextendable dual-labeled fluorogenic hybridization probe
during extension that is quantitatively measured by using
a combined thermal cycler-fluorescence detector. This
system eliminates the time-consuming process after PCR,
and is also relatively resistant to carryover contamination
of PCR amplification.
IV. Fletcher et al. (24) used a system in which
telomerase in intact nuclei catalyses primer extention.
Telomerase activity in isotonically isolated nuclei from
human CEM cells shows low processivity (addition of up
to four TTAGGG repeats). Examination of telomerase
activity in a more natural nuclear environment may shed
new light on the telomerase function and provide a useful
system for evaluation of new telomerase inhibitors.
Assessment of the clinical utility of activity
measurement for prognostic evaluation awaits more

Methods

Source

Original TRAP assay
Fluorescent-TRAP
Stretch-PCR
Stretch-PCR and PicoGreen
In situ TRAP
TMA/HPA
RT-PCR
Real-time PCR
Telomerase in intact nuclei

Kim et al., 1994
Aldous and Grabill,1997
Tatematsu et al., 1996
Gelmini et al., 1998
Ohyashiki et al., 1997
Hirose et al., 1998
Kyo et al., 1999; Sumida et al., 1999; Harada et al., 2000
Yajima et al., 1998
Fletcher et al., 1999
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conclusive studies of large numbers of samples with
strictly quantitative methods of telomerase analysis or the
development of methods.

Assessment
If the TRAP method should be used for the
determination of telomerase activity, the use of stretchPCR with PicoGreen must be preferred. The primers
contain unrelated tag sequences at 5' termini in this
method, and so they do not anneal the internal sequences
of the telomerase products. Thus the occurrence of
shorter products is prevented (13). In addition, there is
no time-consuming post-PCR procedure such as gel

electrophoresis. If the RT-PCR method should be used for
the determination of telomerase activity, the level of
hTERT expression must be chosen because there is a close
correlation between hTERT expression and telomerase
activity (19,20).
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